Mitoxantrone Hydrochloride Liposome

Phase 3Small molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Mitoxantrone Hydrochloride Liposome is one of 326 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

325

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

LymphomaActive, not recruiting

Neuromyelitis OpticaActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Multiple SclerosisActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Neuromyelitis OpticaPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 1

Active, not recruiting

Diffuse Large B-Cell LymphomaPreclinical

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Soft Tissue SarcomaPhase 1

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Mitoxantrone Hydrochloride Liposome

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

3 2

DATROWAY

Daiichi Sankyo

Preclinical

4 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Preclinical

—10

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ANot yet recruiting

Diffuse Large B-Cell Lymphoma

NCT05990985

Q2 2027

Phase 2Not yet recruiting

Nasopharyngeal Cancer

NCT06892431

Phase 2Recruiting

Relapsed/refractory

NCT06489808

Q3 2027

Phase 1/2Recruiting

Diffuse Large B-Cell Lymphoma

NCT06594640

Phase 3Not yet recruiting

Nasopharyngeal Carcinoma

NCT05717764

Phase 2Recruiting

Recurrent or Metastatic NPC

NCT06472713

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma6 trials

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05784987·60 enrolled

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT06594640·108 enrolled

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Unknown status·JJianfeng Zhou·Phase 2·NCT05575973·55 enrolled

Show 3 more trials

R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05777369·30 enrolled

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05875428·104 enrolled

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Not yet recruiting·TThe First Hospital of Jilin University·N/A·NCT05990985·20 enrolled

Lymphoma5 trials

Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors

Active, not recruiting·SSun Yat-sen University·Phase 1·NCT05620862·68 enrolled

A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

Unknown status·SSun Yat-sen University·Phase 1/2·NCT05527275·78 enrolled

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting·SSun Yat-sen University·Phase 1/2·NCT07093710·101 enrolled

Show 2 more trials

A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT03776279·106 enrolled

Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT05173545·24 enrolled

Treatment3 trials

VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06447090·30 enrolled

Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06621212·72 enrolled

Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06434662·34 enrolled

Breast Cancer3 trials

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Unknown status·—·N/A·NCT06156761·24 enrolled

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Terminated· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT04927481·28 enrolled

A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT02596373·60 enrolled

Lip2 trials

Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT02043756·20 enrolled

Phase I Study of Mitoxantrone Hydrochloride Liposome Injection

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT02131688·30 enrolled

20 more indications

Newly Diagnosed2 trials

Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06621199·42 enrolled

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT07486479·204 enrolled

Relapsed/Refractory2 trials

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06489808·89 enrolled

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Active, not recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT04668690·193 enrolled

Acute Myeloid Leukemia2 trials

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Terminated· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT05345938·1 enrolled

A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT05100303·58 enrolled

Nasopharyngeal Carcinoma2 trials

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Recruiting·MMing-Yuan Chen·Phase 2·NCT07070479·208 enrolled

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Not yet recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 3·NCT05717764·500 enrolled

Patients With Advanced Solid Tumors2 trials

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04921878·29 enrolled

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT05344742·116 enrolled

PTCL1 trial

Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07372352·26 enrolled

Malignant Tumor1 trial

A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor

Suspended· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05089461·120 enrolled

Induction Therapy1 trial

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Recruiting·—·Phase 2·NCT06221683·500 enrolled

Infusion1 trial

A Study of Mitoxantrone Hydrochloride Liposome Infusion

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT02856685·60 enrolled

Nasopharyngeal Cancer1 trial

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06892431·150 enrolled

Advanced Solid Tumor1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04719065·90 enrolled

Metastatic Head and Neck Cancer1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04902027·45 enrolled

Soft Tissue Sarcoma1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Terminated· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04900766·31 enrolled

Pancreatic Cancer1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05100329·38 enrolled

Gastric Carcinoma1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Terminated· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04718402·21 enrolled

Multiple Sclerosis1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

Withdrawn·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 2·NCT05496894

Recurrent or Metastatic NPC1 trial

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Recruiting·MMing-Yuan Chen·Phase 2·NCT06472713·32 enrolled

Ovarian Cancer1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Terminated· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04718376·56 enrolled

Neuromyelitis Optica1 trial

Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Completed·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 2·NCT05551598·46 enrolled

Dexamethasone1 trial

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Unknown status·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 1·NCT05052970·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 44 trial records for Mitoxantrone Hydrochloride Liposome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mitoxantrone Hydrochloride Liposome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mitoxantrone Hydrochloride Liposome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Mitoxantrone Hydrochloride Liposome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma6 trials

Lymphoma5 trials

Treatment3 trials

Breast Cancer3 trials

Lip2 trials

Newly Diagnosed2 trials

Relapsed/Refractory2 trials

Acute Myeloid Leukemia2 trials

Nasopharyngeal Carcinoma2 trials

Patients With Advanced Solid Tumors2 trials

PTCL1 trial

Malignant Tumor1 trial

Induction Therapy1 trial

Infusion1 trial

Nasopharyngeal Cancer1 trial

Advanced Solid Tumor1 trial

Metastatic Head and Neck Cancer1 trial

Soft Tissue Sarcoma1 trial

Pancreatic Cancer1 trial

Gastric Carcinoma1 trial

Multiple Sclerosis1 trial

Recurrent or Metastatic NPC1 trial

Ovarian Cancer1 trial

Neuromyelitis Optica1 trial

Dexamethasone1 trial

References

Drug Info

Quick Facts

Related News